Remove Bioinformatics Remove Genetic Engineering Remove Genetics Remove Production
article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. About Teneobio Teneobio, Inc.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

“As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin,” said Martine Rothblatt , Ph.D., SILVER SPRING, Md.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Marketing Product Manager, Product, NanoTemper Technologies. The luncheon presentation will be done by James Keck, PhD, President’s Innovation Fellow and Senior Director, Innovation and Product Development, Product Development, The Jackson Laboratory.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’. Paul Dyer, PhD, Field Application Scientist, Halo Labs, on: ‘Total particle analysis with aura; pathway to USP validation and product release’.